ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES IN THE NEW ERA OF PAYMENT REFORM: UNITED STATES PAYER PERCEPTIONS

被引：0
|
作者：
Hogue, S. [1 ]
Brogan, A. P. [1 ]
Croft, E. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] RTI Hlth Solut, Manchester, Lancs, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP25
引用
下载
收藏
页码：A74 / A74
页数：1
相关论文
共 10 条
  • [1] ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS
    Hogue, S.
    Brogan, A. P.
    Croft, E.
    VALUE IN HEALTH, 2015, 18 (07) : A681 - A681
  • [2] REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?
    Macaulay, R.
    Khatri, U.
    VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [3] Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
    Morrell, Liz
    Wordsworth, Sarah
    Fu, Howell
    Rees, Sian
    Barker, Richard
    BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [4] Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
    Liz Morrell
    Sarah Wordsworth
    Howell Fu
    Sian Rees
    Richard Barker
    BMC Health Services Research, 17
  • [5] THE NEW SMC ULTRA-ORPHAN PATHWAY: HTA BEST PRACTICE FOR VERY RARE DISEASES?
    Carr, D.
    Macaulay, R.
    VALUE IN HEALTH, 2021, 24 : S241 - S241
  • [6] Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?
    Hyde, Rebecca
    Dobrovolny, Diana
    AMERICAN HEALTH AND DRUG BENEFITS, 2010, 3 (01): : 15 - 22
  • [7] PAYER PERSPECTIVES ON DRUG PRICING, COVERAGE, AND REIMBURSEMENT IN OPHTHALMOLOGIC ORPHAN CONDITION IN THE UNITED STATES
    Gavaghan, M.
    Abraham, J.
    Pauer, L.
    VALUE IN HEALTH, 2013, 16 (03) : A10 - A10
  • [8] PAYER MANAGEMENT AND PRICING DYNAMICS FOR NON-ONCOLOGY PHARMACY BENEFIT ORPHAN DRUGS FOR RARE DISEASES IN THE UNITED STATES LAUNCHED 2004-2014
    Dalsania, R. R.
    Leibfried, M. J.
    Richardson, S. K.
    VALUE IN HEALTH, 2014, 17 (03) : A226 - A226
  • [9] The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
    Frank R. Lichtenberg
    The European Journal of Health Economics, 2013, 14 : 41 - 56
  • [10] The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007
    Lichtenberg, Frank R.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (01): : 41 - 56
1